NSEGeneral Updates13 Aug 2026 · 13 Aug 2026, 02:35 pm
General Updates
FDC Limited · FDC
✦ AI Summary▲ PositiveOrder Win
FDC Limited's subsidiary, FDC International Ltd, received marketing authorisation from MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment7/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
FDC Limited has informed the Exchange about Marketing Authorisation received by its subsidiary, FDC International Ltd, from MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.
Attachments (1)
📄pdf
Download →
FDC_13082026143437_MHRAapprovalAtropineeyedropssign.pdf
View document text
Date : August 13, 2026
To, National Stock Exchange of India Ltd.
BSE Limited Exchange Plaza, Plot no. C/1,
Phiroze Jeejeebhoy Towers, G Block, Bandra-Kurla Complex,
Dalal Street,Mumbai- 400 001 Bandra (E), Mumbai - 400 051
BSE Script Code: 531599 NSE Symbol: FDC
Subject: Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) – Grant of Marketing
Authorisation from MHRA, UK for Atropine 1.0% w/v Eye Drops, Solution.
Dear Sir/Madam,
This is to inform you that the Company’s Subsidiary, FDC International Limited has received Marketing
Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), United
Kingdom, for Atropine 1.0% w/v Eye Drops, Solution.
Kindly take the same on record.
Thanking you,
Yours truly,
For FDC LIMITED
Varsharani Katre
Company Secretary & Legal Head
Membership No. F-8948